NASDAQ:FLNA Cassava Sciences (FLNA) Stock Price, News & Analysis $0.93 -0.03 (-3.53%) As of 10/2/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Cassava Sciences Stock (NASDAQ:FLNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cassava Sciences alerts:Sign Up Key Stats Today's Range$0.93▼$1.0450-Day Range$0.68▼$1.0352-Week Range$0.67▼$4.98Volume1.68 million shsAverage Volume5.67 million shsMarket Capitalization$44.97 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on simufilam, an investigational oral therapy designed to target an altered form of the scaffolding protein filamin A that Cassava has linked to Alzheimer’s disease pathology. Simufilam has been evaluated in clinical studies involving patients with Alzheimer’s disease, but it is an investigational product and is not approved for commercial use. Cassava Sciences has not marketed any approved products and has primarily operated as a research and development company serving the pharmaceutical and biotechnology markets. Founded in 1998 as Pain Therapeutics, the company adopted the name Cassava Sciences in 2018. It is headquartered in Austin, Texas, and was founded by Remi Barbier, who has served as its chief executive officer. Cassava Sciences is generally associated with the Nasdaq ticker SAVA; the ticker FLNA does not appear to correspond to the company.AI Generated. May Contain Errors. Read More Cassava Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreFLNA MarketRank™: Cassava Sciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 342nd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCassava Sciences has a consensus price target of $5.00, representing about 437.1% upside from its current price of $0.93.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.49% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 18.69, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 1.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.09 News SentimentCassava Sciences has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Cassava Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for FLNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $356,328.00 in company stock, which represents 0.7923% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $356,328.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders4.60% of the stock of Cassava Sciences is held by insiders.Percentage Held by Institutions38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Receive FLNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLNA Stock News HeadlinesFilana CEO buys 306,813 sharesOctober 4 at 4:02 AM | americanbankingnews.comCassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Buys 100,000 SharesOctober 3 at 4:39 AM | americanbankingnews.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.October 4 at 1:00 AM | Base Camp Trading (Ad)Cassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Acquires 206,813 SharesOctober 3 at 4:39 AM | americanbankingnews.comCassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Purchases 100,000 SharesOctober 2 at 5:22 AM | insidertrades.comCassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Buys 93,091 SharesOctober 2 at 4:38 AM | americanbankingnews.comCassava Sciences (NASDAQ:FLNA) CEO Richard Barry Buys 93,091 Shares of StockOctober 1 at 5:22 AM | insidertrades.comPositive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research ForwardSeptember 22, 2026 | benzinga.comSee More Headlines FLNA Stock Analysis - Frequently Asked Questions How have FLNA shares performed this year? Cassava Sciences' stock was trading at $1.98 on January 1st, 2026. Since then, FLNA shares have decreased by 53.0% and is now trading at $0.9309. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:FLNA) announced its quarterly earnings results on Wednesday, July, 29th. The company reported ($0.18) EPS for the quarter. When did Cassava Sciences' stock split? Shares of Cassava Sciences split before market open on Thursday, December 21st 2023.The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. How do I buy shares of Cassava Sciences? Shares of FLNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings7/29/2026Today10/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 FLNA's financial health is in the Red zone, according to TradeSmith. FLNA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:FLNA Previous SymbolNASDAQ:SAVA CIK1069530 Webcassavasciences.com Phone512-501-2444Fax512-501-0414Employees30Year Founded1998Price Target and Rating Average Price Target for Cassava Sciences$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+437.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.78% Return on Assets-36.74% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.60Miscellaneous Outstanding Shares48,310,000Free Float46,086,000Market Cap$44.97 million OptionableOptionable Beta-0.65 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:FLNA) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
